Hohaus, Stefan
 Distribuzione geografica
Continente #
EU - Europa 5.871
NA - Nord America 5.466
AS - Asia 1.851
AF - Africa 43
SA - Sud America 36
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.294
Nazione #
US - Stati Uniti d'America 5.419
DE - Germania 2.019
SE - Svezia 1.056
CN - Cina 927
PL - Polonia 673
IT - Italia 572
SG - Singapore 484
UA - Ucraina 453
FR - Francia 255
IE - Irlanda 244
GB - Regno Unito 221
ID - Indonesia 157
FI - Finlandia 131
IN - India 131
RU - Federazione Russa 108
TR - Turchia 48
CA - Canada 41
CI - Costa d'Avorio 34
BE - Belgio 32
JP - Giappone 26
AU - Australia 21
BR - Brasile 21
VN - Vietnam 21
CZ - Repubblica Ceca 20
IR - Iran 20
CH - Svizzera 12
NL - Olanda 12
RO - Romania 10
ES - Italia 8
LT - Lituania 8
CO - Colombia 7
HK - Hong Kong 7
MY - Malesia 7
GR - Grecia 6
IL - Israele 6
AE - Emirati Arabi Uniti 5
AT - Austria 5
NO - Norvegia 5
EU - Europa 4
PT - Portogallo 4
BG - Bulgaria 3
CU - Cuba 3
DK - Danimarca 3
EC - Ecuador 3
ZA - Sudafrica 3
BD - Bangladesh 2
CL - Cile 2
CY - Cipro 2
KR - Corea 2
LU - Lussemburgo 2
LV - Lettonia 2
MA - Marocco 2
MX - Messico 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
AR - Argentina 1
BN - Brunei Darussalam 1
DZ - Algeria 1
GH - Ghana 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
SA - Arabia Saudita 1
SI - Slovenia 1
TH - Thailandia 1
UY - Uruguay 1
Totale 13.294
Città #
Chandler 1.057
Warsaw 663
Ashburn 427
Singapore 365
Jacksonville 344
Dublin 239
San Mateo 227
Nanjing 226
Ann Arbor 207
Fairfield 199
Woodbridge 198
Dearborn 196
Houston 193
Wilmington 182
Jakarta 154
New York 135
Nürnberg 128
Milan 117
Seattle 105
Cattolica 98
Rome 93
Bremen 90
Munich 86
Moscow 85
Nanchang 85
Beijing 81
Redmond 77
Lawrence 74
Los Angeles 72
Boston 71
Redwood City 70
Princeton 58
Kunming 57
Marseille 56
Chicago 52
Cambridge 47
Lancaster 46
Izmir 39
Helsinki 38
Shanghai 36
Norwalk 35
Abidjan 34
Hebei 33
Hangzhou 32
Mountain View 31
Shenyang 30
Zhengzhou 30
Brussels 29
Boardman 28
Jiaxing 28
Auburn Hills 25
Tianjin 25
Fremont 24
Leawood 24
Changsha 23
Guangzhou 23
London 23
University Park 21
Hefei 20
Jinan 16
Augusta 15
Brno 15
Pune 15
Santa Clara 14
Falls Church 13
Florence 13
Costa Mesa 12
Toronto 12
Dong Ket 11
Frankfurt am Main 10
Lanzhou 10
Andover 9
Berlin 9
Hanoi 9
Monmouth Junction 9
São Paulo 9
Kish 8
Philadelphia 8
San Diego 8
Simi Valley 8
Sydney 8
Washington 8
Alghero 7
Chengdu 7
Edinburgh 7
Kraków 7
Bogotá 6
Changchun 6
Detroit 6
Enterprise 6
Mumbai 6
Naples 6
Ottawa 6
Phoenix 6
Verona 6
Ypsilanti 6
Bologna 5
Buffalo 5
Hyderabad 5
Jesi 5
Totale 7.648
Nome #
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 355
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 304
Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy 285
Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization 267
Fanconi anemia gene variants in therapy-related myeloid neoplasms 259
Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients 235
THE PROGNOSTIC ROLE OF EBV IN PERIPHERAL BLOOD OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA 231
Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker 211
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. 184
Italian real-life experience with brentuximab vedotin: Results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 177
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis 170
Anemia in Diffuse Large B cell Non-Hodgkin Lymphoma: The Role of IL-6, Hepcidin and Erythropoietin 166
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 154
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma 153
Prospective study of hepatitis B virus reactivation in patients with hematological malignancies 147
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 138
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 136
Why methylation is not a marker predictive of response to hypomethylating agents 136
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 135
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 133
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 133
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 132
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 130
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 127
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 127
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 124
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. 122
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 121
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 118
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine 116
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 115
Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms : Long-Term Experience. 115
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 113
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication 111
Iron in Hodgkin's lymphoma 110
Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). 110
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. 109
Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-term experience 108
Epigenetic changes in therapy-related MDS/AML 107
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 107
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 104
A T cell lymphoblastic lymphoma with mucormycosis as unusual etiology of acute cerebral ischemia 104
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 102
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. 102
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma 102
Intravascular large B-cell lymphoma presenting as slowly progressive paraparesis with normal MRI features 101
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 101
Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance 101
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 100
PU.1 and CEBPA expression in acute myeloid leukemia. 98
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 98
Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance 98
Primary multifocal lymphoma of peripheral nervous system: Case report and review of the literature 97
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. 96
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 96
Outcome of therapy-related myeloid neoplasms treated with azacitidine 95
Clinical and prognostic features of lymphomas arising in the head and neck region: Our experience of preferential association of different histotypes with various sites of origin in ninety patients 95
Intravascular large-B cell lymphoma: when lymphoma is suspected but routine diagnostic work-up is negative. 94
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma 93
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. 93
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 92
Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma 92
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. 90
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 90
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 90
Clonal evolution in therapy-related neoplasms 90
Primary pancreatic lymphoma in a patient with maturity onset diabetes of the young type 3 88
Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference 88
Granulocyte transfusions as adjunctive treatment of invasive fungal diseases in neutropenic patients 87
Small lymphocytic lymphoma in a patient with Fabry disease 86
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. 86
Mantle cell lymphoma relapsing at the lymphedematous arm 86
Prognostic factors in hodgkin lymphoma 86
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 86
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. 85
Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment 84
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 82
Desensitization to thalidomide in a patient with multiple myeloma 80
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 80
Small lymphocytic lymphoma in a patient with Fabry disease 80
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 79
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 79
FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET) 79
Comorbidity assessment to determine prognosis in older adult patients with classical Hodgkin lymphoma 79
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 78
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 77
Burkitt's lymphoma of the breast metastatic to the ovary diagnosed during pregnancy 77
Negative prognostic value of glutathione s-transferase (gstm1 and gstt1) deletions in adult acute myeloid leukemia. 76
Dural MALT Lymphoma Detected by 11C-Methionine PET/CT 76
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 76
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. 73
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 72
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma 71
Muscle Recurrence of a Primarily Nodal Follicular Lymphoma Studied by Contrast-Enhanced 18F-FDG PET/CT 71
The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL) 70
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 69
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 69
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 68
Cognitive Decline in Older Long-Term Survivors From Non-Hodgkin Lymphoma: A Multicenter Cross-Sectional Study 66
Burkitt lymphoma as fourth neoplasia in a patient affected by cowden syndrome with a novel PTEN germline pathogenic variant 65
Totale 11.499
Categoria #
all - tutte 51.277
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.277


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.375 0 0 0 0 201 248 190 83 173 135 209 136
2020/20211.532 50 184 52 127 182 147 180 37 149 83 290 51
2021/20221.311 154 113 22 54 86 36 38 207 64 105 211 221
2022/20232.909 392 403 207 511 180 358 142 232 310 49 85 40
2023/20241.313 56 390 42 66 39 207 52 87 11 39 153 171
2024/2025876 100 115 252 161 248 0 0 0 0 0 0 0
Totale 13.489